O'Connor Donal 4
4 · Theravance Biopharma, Inc. · Filed Jun 16, 2026
Research Summary
AI-generated summary of this filing
Theravance Biopharma Director Donal O'Connor Receives Equity Award
What Happened
Donal O'Connor, a director of Theravance Biopharma (TBPH), was granted equity on 2026-06-12. The filing shows an award/acquisition of 6,009 shares at $0.00 and a derivative award of 13,398 shares (also $0.00). No cash was paid for these awards; the total reported acquisition amount is $0.
Key Details
- Transaction date: 2026-06-12; Form 4 filed 2026-06-16 (filed within the SEC’s two-business-day window).
- Grants: 6,009 shares (direct award) and 13,398 derivative shares (award of equity-linked instrument) at $0.00 per share.
- Shares owned after transaction: Not specified in this filing.
- Footnote (F1): The derivative award vests 1/12th per month of service after the grant date, with any remaining unvested shares vesting on the next annual shareholders’ meeting provided the director remains in continuous service.
- Transaction code: A = Award/Grant (derivative indicates an option/RSU-like instrument).
Context
This was an equity grant to a director, not an open-market purchase or sale. Awards at $0.00 are typical for stock-based compensation and are intended to align insider and shareholder interests; they are not direct indications of immediate buying/selling intent. The derivative component carries a monthly vesting schedule with a catch-up vesting at the next annual meeting per the footnote.
Insider Transaction Report
- Award
Ordinary Shares
2026-06-12+6,009→ 80,213 total - Award
Share Option (Right to Buy)
[F1]2026-06-12+13,398→ 13,398 totalExercise: $16.64Exp: 2036-06-11→ Ordinary Shares (13,398 underlying)
Footnotes (1)
- [F1]This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.